Ysios Capital, a Spanish venture capital firm dedicated to the biotechnology sector, has closed its third fund, Ysios BioFund III (YBF III), on €216m, exceeding its initial target.
Laboratory and imaging diagnostics service is valued at more than EUR 5bn
IK expanded its UK operations to include a local small-cap team headed by partner Tom Salmon in 2020
Asset manager nets a 10.7% IRR on the investment in its listed peer
Romanian cybersecurity company appoints JP Morgan and Morgan Stanley for a dual-track process